This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
China Renaissance Remains a Buy on Wuxi Biologics (Cayman) (WXIBF)
China Renaissance analyst maintained a Buy rating on Wuxi Biologics (Cayman) yesterday and set a price target of HK$54.23. The company’s shares closed yesterday at HK$40.02.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wuxi Biologics (Cayman) has an analyst consensus of Strong Buy, with a price target consensus of HK$42.45.
WXIBF market cap is currently HK$155.9B and has a P/E ratio of 34.31.
Read More on WXIBF:
Disclaimer & DisclosureReport an Issue
- WuXi Biologics Forecasts Strong 2025 Profit Growth on Expanded Services and Efficiency Gains
- WuXi Biologics Sets March 24 Board Meeting to Approve 2025 Annual Results
- WuXi Biologics’ Substantial Shareholder to Cut Stake via HK$38.52 Block Trade
- Citigroup-Backed HK$4.00 Cash Offer Launched for Wuxi Biologics Shares at 99% Premium
- WuXi Biologics Highlights Strong 2025 Pipeline and Growth Ahead of J.P. Morgan Healthcare Conference
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
